Analysis of:
$300 to Learn Risk of Cancer of the Prostate (www.nytimes.com)
We can now determine with genetic tests who is at risk for developing PC. ProActive Genetics. The more genetic variants found, the greater the risk of PC. 4 or 5 variants increased ones risk x 4.5.
Analysis of:
Sirolimus Reduces Size of Angiomyolipoma Tumors (www.medscape.com)
Sirolimus has shown activity in shrinking benign tumors associated with tuberous sclerosis......opens the door for further exploration alone and combo in other mTOR driven disorders
Analysis of:
Neuropilin-2 May Offer New Therapeutic Target in Colon Cancer (www.medscape.com)
Targeting this protein MAY offer a therapeutic alternative or "add on" in GI malignancies.
Analysis of:
Sirolimus Reduces Size of Angiomyolipoma Tumors (www.medscape.com)
In 2 small studies, Wyeth's M-tor inhibitor, Sirolimus, decraesed size of benign tumors in patients with Tuberous sclerosis and even improved lung function in one study.
Sirolimus may have a role outside renal cancer in hematological malignancies , sracomas, as well as melanoma.
Analysis of:
Sirolimus Reduces Size of Angiomyolipoma Tumors (www.medscape.com)
Sirolimus reduces the size of "benign" tumors found in tuberous sclerosis.
Analysis of:
Amgen's Outlook Brightens (online.wsj.com)
Amgen's ESA's ( Aranesp and Epgen) use is expected to decline amongst oncologists and nephrologists even if Medicare revises its guidelines, which is in doubt. Osteoporosis is a crowded market with already many approved drugs. Amgen's denosumab which lacks superiority data to these agents is unliokely...
Analysis of:
The New Insurance Frontier (www.healthleadersmedia.com)
The wall street Journal article about the currently "uninsured" population is on target. Most of these individuals are employed, young, and healthy, but are afraid of high prices, a lot of paperwork and also are under false pretense taht they are " at low risk". Insurnace companies which do their homework:...
Analysis of:
FDA extends NDA review period of SC methylnaltrexone from Wyeth (www.pipelinereview.com)
Methylnaltrexone ( Progenics, Wyeth) is being developed in subcutaneous formulation for treatment of opioid induced constipation ( OIC) in patients receiving palliative and supportive care. FDA has requested resulkts from studies involving IV formulation to verify taht the drug is not associated...
Analysis of:
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer (www.reuters.com)
Exilexis XL-184 is an oral small molecules that target many receptor tyrosinae kinases ( RTK's) like MET, RET and VEGFR , which is being tested in Phase I/II trial with and without Tarceva in patients with NSCLC. The fact that early phase trials showed no incraesed cardiac side...